Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections
Molecules · 27.06.2023 · 28 (13) · 5032
DOI: 10.3390/molecules28135032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 27.06.2023. Verfasst von Fernanda S Rasquel-Oliveira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Pathology, Center of Biological Sciences, Londrina State University, Londrina…. Hauptthemen laut MEDLINE: Fatty Acids, Omega-3, Parasitic Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Fundação Araucária.
Abstract (Originalsprache)
During an infection, inflammation mobilizes immune cells to eliminate the pathogen and protect the host. However, inflammation can be detrimental when exacerbated and/or chronic. The resolution phase of the inflammatory process is actively orchestrated by the specialized pro-resolving lipid mediators (SPMs), generated from omega-3 and -6 polyunsaturated fatty acids (PUFAs) that bind to different G-protein coupled receptors to exert their activity. As immunoresolvents, SPMs regulate the influx of leukocytes to the inflammatory site, reduce cytokine and chemokine levels, promote bacterial clearance, inhibit the export of viral transcripts, enhance efferocytosis, stimulate tissue healing, and lower antibiotic requirements. Metabolomic studies have evaluated SPM levels in patients and animals during infection, and temporal regulation of SPMs seems to be essential to properly coordinate a response against the microorganism. In this review, we summarize the current knowledge on SPM biosynthesis and classifications, endogenous production profiles and their effects in animal models of bacterial, viral and parasitic infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Pathology, Center of Biological Sciences, Londrina State University, Londrina 86057-970, Paraná, Brazil.
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
- Department of Pharmaceutical Sciences, Center of Health Science, Londrina State University, Londrina 86038-440, Paraná, Brazil.
ORCID-Profile: Fernanda S Rasquel-Oliveira, Matheus Deroco Veloso da Silva, Geovana Martelossi-Cebinelli, Victor Fattori, Rubia Casagrande, Waldiceu A Verri
Förderung
- National Council for Scientific and Technological Development
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Fundação Araucária
- Financiadora de Estudos e Projetos
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Decit/SCTIE/MS
- SETI/Fundação Araucária
- Financiadora de Estudos e Projetos—FINEP
Zitieren
APA
Rasquel-Oliveira, F. S., Silva, M. D. V. D., Martelossi-Cebinelli, G., Fattori, V., Casagrande, R., & Verri, W. A. (2023). Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections. Molecules, 28(13), 5032. https://doi.org/10.3390/molecules28135032
Vancouver
Rasquel-Oliveira FS, Silva MDVD, Martelossi-Cebinelli G, Fattori V, Casagrande R, Verri WA. Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections. Molecules. 2023;28(13):5032. doi:10.3390/molecules28135032
BibTeX
@article{RasquelOliveira2023,
author = {Rasquel-Oliveira, Fernanda S and Silva, Matheus Deroco Veloso da and Martelossi-Cebinelli, Geovana and Fattori, Victor and Casagrande, Rubia and Verri, Waldiceu A},
title = {Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections},
journal = {Molecules},
year = {2023},
volume = {28},
number = {13},
pages = {5032},
doi = {10.3390/molecules28135032}
}
EUVIMED